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Objective. To investigate the associations between anti-nuclear matrix protein 2 (anti-NXP-2) autoantibody levels and disease activity as well as calcinosis severity in patients with idiopathic inflammatory myopathies (IIMs).
Methods. Serum levels of anti-NXP-2 autoantibodies were determined in 709 patients with IIMs and also serially measured in the patients' sera with an in-house enzyme-linked immunosorbent assay using MORC3 recombinant protein. Patients with anti-NXP-2 autoantibodies were divided into 2 subgroups: those with and those without calcinosis. Associations of anti-NXP-2 autoantibody levels with organ-specific disease activity (using 10-cm visual analog scale [VAS] scores), serum creatine kinase (CK) levels, and calcinosis severity were investigated in cross-sectional and longitudinal analyses.
Results. A cross-sectional analysis of 56 IIM patients with anti-NXP-2 autoantibodies (38 without calcinosis and 18 with calcinosis) showed that in patients without calcinosis, the levels of anti-NXP-2 autoantibodies were positively correlated with the physician's global assessment of disease activity and muscle VAS scores and serum CK levels, whereas no such association was found in patients with calcinosis. Results of the longitudinal study revealed strong correlations of anti-NXP-2 antibody levels with the physician's global assessment and constitutional, cutaneous, gastrointestinal, and muscle VAS scores and serum CK levels in patients without calcinosis, but in patients with calcinosis, only a moderate correlation was observed between anti-NXP-2 antibody levels and the physician's global VAS and constitutional VAS scores. Of note, in patients without calcinosis, anti-NXP-2 autoantibodies were found to disappear during periods of clinical remission, but reappeared with disease relapse. No association between anti-NXP-2 antibody levels and the severity of calcinosis was observed.
Conclusion. These findings indicate that anti-NXP-2 autoantibodies serve as a useful marker for disease activity in patients with IIMs, especially in the absence of calcinosis. The differential associations observed between anti-NXP-2 autoantibody levels and disease activity suggest that there may be a phenotypic difference between patients with and those without calcinosis.
The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune muscle diseases with a clinical presentation of muscular inflammation and/or dermatitis (1) . The presence of a number of disease-specific autoantibodies, known as myositis-specific autoantibodies (MSAs), is also a prominent feature of the IIMs. MSAs are strongly associated with distinct clinical phenotypes, and thus they can be used to classify patients into subgroups based on homogeneity of clinical features (2, 3) .
Anti-nuclear matrix protein 2 (anti-NXP-2) autoantibodies, a type of MSA that targets a 140-kd protein, were first reported in a US cohort of patients with juvenile dermatomyositis (DM) (4) . Subsequent studies by Targoff et al identified the 140-kd autoantigen target as being NXP-2 (also known as MORC3), a protein involved in transcriptional regulation (5) . To date, several cohort studies from different countries have found these autoantibodies both in juvenile IIM cohorts and in adult patients with IIM, at a wide spectrum of frequencies (1.6-30% of patients) (6) (7) (8) (9) (10) (11) (12) (13) (14) . In terms of the clinical associations of anti-NXP-2 autoantibodies, calcinosis is one of the predominant complications reported so far (15, 16 ). However, whether the level of these autoantibodies can serve as a useful biomarker of calcinosis severity and as a predictor of calcinosis in patients with IIMs remains an enigma.
In addition, several studies found that another vital phenotype in IIM patients with anti-NXP-2 antibodies is severe muscle disease, characterized primarily by a greater degree of muscle weakness, dysphagia, and elevated creatine kinase (CK) levels (9, 11, 13, 14, 17) . These features of muscle involvement as major clinical manifestations were also reported in patients with 2 other types of MSAs, anti-signal recognition particle (anti-SRP) autoantibodies and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) autoantibodies (18, 19) , the presence of which may be indicative of their pathogenic role in the process of muscle damage. The levels of both anti-SRP antibodies and anti-HMGCR antibodies were reported to be associated with the extent of disease activity in IIMs (20) (21) (22) . However, no detailed studies concerning a potential association between disease activity and the levels of anti-NXP-2 autoantibodies have been reported thus far.
Quantitation of autoantibody levels may be helpful in monitoring disease activity, treatment response, and risk of flare, potentially contributing to a better understanding of the pathogenesis of the disease. The present study was therefore designed to examine the relationship between anti-NXP-2 antibody levels and disease activity, as well as calcinosis severity, in patients with IIMs. Furthermore, whether the anti-NXP-2 autoantibody levels could be used to identify patients who may be at higher risk of developing calcinosis was also evaluated.
PATIENTS AND METHODS
Patients. The present study included patients with IIMs from a large cohort of individuals who visited the China-Japan Friendship Hospital in Beijing, China between June 2004 and June 2017. The European Neuromuscular Centre (ENMC) 2003 criteria were preferentially adopted for diagnosing polymyositis (PM) and DM (23) , whereas the Bohan and Peter criteria (24, 25) were the second choice for diagnosis when data were insufficient. Clinically amyopathic DM (CADM) was diagnosed according to the criteria proposed by Sontheimer et al (26) . The diagnoses of immune-mediated necrotizing myopathy (IMNM), nonspecific myositis (NSM), and DM sine dermatitis were based on the ENMC 2003 criteria (23) . Patients were classified as having juvenile DM if they were age <16 years at the onset of DM (27) . Moreover, we separated the patients with antisynthetase syndrome into a single category based on the criteria proposed by Connors et al (28) . In the present study, patients with CADM and those with DM sine dermatitis were grouped together with patients with DM. Overlap syndrome or other types of myositis, such as sporadic inclusion body myositis, were excluded.
The study was approved by the Research Review Committee and the Ethics Review Committee of the China-Japan Friendship Hospital. Informed consent was obtained from all patients and/or parents in accordance with the principles of the Declaration of Helsinki.
Serum samples and data collection. Serum samples were routinely collected from the patients at the time of diagnosis, and also during the follow-up in the outpatient clinic or at the time of re-hospitalization. All samples were stored at -80°C. Serum samples obtained at the initial visit were screened for the presence of anti-NXP-2 antibodies with an in-house enzyme-linked immunosorbent assay (ELISA) using recombinant MORC3, and these analyses were also repeated in the follow-up serum samples. Positive ELISA findings for anti-NXP-2 antibodies in the serum, including longitudinal changes after treatments, were subsequently confirmed by immunoprecipitation/Western blotting, as previously described (29) (more details on the immunoprecipitation/ Western blot assay are provided in Supplementary Methods, available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40491/abstract). Single or longitudinal testing of the sera for anti-NXP-2 autoantibodies was performed with the exact serum levels in a single ELISA experiment.
A standardized physician questionnaire was used to obtain details on each patient's complete medical history, physical examination findings, auxiliary examination findings, results of laboratory tests, physician's and patient's/parent's global assessments of disease activity on 10-cm visual analog scales (VAS) (when possible), Myositis Disease Activity Assessment (MYOACT) VAS scores (when possible), as well as treatments and outcomes. This information was obtained for each patient during the initial evaluation, at each re-hospitalization, and at each outpatient clinic visit during follow-up.
Assessment of disease activity. Disease activity in each study participant who was referred to our hospital after September 2010 was assessed independently by 2 physicians (HY and XL) at the time of enrollment and at the subsequent follow-up visits, while disease activity in patients who were enrolled before September 2010 was assessed retrospectively in independent evaluations (performed by HY and XL). For the longitudinal study, disease activity in each subject was estimated by the same physician who did the initial disease activity assessment (HY or XL). All of these measurements of disease activity were carried out with the assessors blinded with regard to the patients' serum anti-NXP-2 autoantibody levels.
Disease activity in the patients with IIMs was evaluated using the MYOACT. This tool uses continuous 10-cm VAS scales to globally score disease activity in 6 extramuscular organ systems (constitutional, cutaneous, joint, gastrointestinal, pulmonary, and cardiac), muscle, and the physician's global assessment of disease activity. In addition, serum CK levels at the time of the clinic visit closest to the time of blood sampling for detection of anti-NXP-2 levels were included in the disease activity analyses.
Clinical remission was defined as no detectable clinical or biochemical disease activity as well as a physician's global assessment of disease activity VAS score of <1 for at least 3 consecutive months. Relapse was defined as the recurrence of active disease (determined on the basis of clinical, biochemical, or radiographic features).
Assessment of calcinosis severity. The diagnosis of calcinosis cutis was based on the clinical examination findings and radiologic imaging. All 18 patients with calcinosis had radiographs confirming the diagnosis available for formal review, with or without magnetic resonance imaging (MRI) findings. If both radiography and MRI were used, the results were grouped together for each patient, because in no case was different information readily apparent between the 2 imaging modalities. Currently, no validated outcome measures are available to solely assess calcinosis severity in patients with IIMs. Therefore, the cutaneous damage item in the Myositis Damage Index (MDI) (30) was used for assessing cutaneous damage, and the calcinosis lesion was presupposed to be the only cutaneous manifestation present.
The calcinosis severity score was recorded on a 10-cm VAS, which was rated independently by 2 observers (HY and WJ) without knowledge of the patients' serum anti-NXP-2 autoantibody levels. Interobserver disagreements with regard to calcinosis severity and its changes were resolved by consensus. The scoring took into account not only the density (less dense than trabecular bone versus similar to trabecular bone versus similar to or more dense than bone cortex), area, and number of separate sites of calcinosis, but also the sequelae of the lesions (such as limitation of motion, scarring, and pain). For example, calcinosis with extensive subcutaneous exoskeleton resulting in extreme loss of function could have a maximum value of 10.
Development of the anti-NXP-2 antibody ELISA. An ELISA system using a recombinant protein as an antigen was developed as previously described (20, 31) , with some modifications. Briefly, 96-well polyvinyl plates were coated with purified recombinant MORC3 protein (50 ng/well) (Origene Technologies) in a carbonate buffer (pH 9.6) at 4°C overnight. The patients' serum (dilution ≥1:250) was incubated with MORC3-coated ELISA plates for 1 hour at 37°C. Subsequently, horseradish peroxidase-conjugated goat anti-human IgG (dilution 1:50,000) (Abcam) was used to detect anti-MORC3 binding. All samples were examined in duplicate, and the antibody units were calculated from the optical density at 450 nm, with reference to a standard curve constructed using serial concentrations of a serum sample containing a high titer of anti-NXP-2 autoantibodies. Quantitative values (in units/ml) for anti-NXP-2 autoantibody levels were assigned using a standard curve, consisting of 1, 2, 4, 8, 16, 32, 64, and 128 units (where 64 units = 1:250 dilution of the standard serum sample used for all ELISA runs). A typical representative standard curve of anti-NXP-2 autoantibody levels is shown in Supplementary Figure 1 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40491/abstract). In several cases in which a given serum sample diluted to 1:250 was not within the linear range of the assay, a further dilution to 1:1,000 was performed. The cutoff level was set at 3.2 units, based on 5 standard deviations above the mean value of 50 healthy control sera.
Statistical analysis. Continuous data are expressed as the mean AE SD or median (interquartile range [IQR] ). For non-normally distributed data, the Mann-Whitney U test was used for comparisons of 2 independent samples. Categorical data were analyzed using Fisher's exact test. P values less than 0.05 were considered statistically significant.
A series of Spearman's rank correlation tests was conducted in IIM patients with anti-NXP-2 autoantibodies from the total cohort, as well as in patients stratified by the presence or absence of calcinosis, to examine the cross-correlation of anti-NXP-2 autoantibodies with disease activity. The test was also undertaken to explore the correlation of anti-NXP-2 autoantibody levels with calcinosis severity. In patients for whom serial longitudinal samples were available, a mixed linear regression analysis was performed to determine the correlation between anti-NXP-2 autoantibody levels and disease activity over time.
RESULTS
Identification of anti-NXP-2 autoantibodies in the serum of patients with IIMs. After the initial screening by ELISA, we found that the sera from 53 patients with IIMs were positive for anti-NXP-2 autoantibodies, while the sera from 12 patients showed equivocal findings and those from 644 patients were negative for anti-NXP-2 autoantibodies. Of these, 52 serum samples that were identified as anti-NXP-2 positive by ELISA and 4 serum samples that were identified as equivocal for anti-NXP-2 antibodies by ELISA were also positive in the immunoprecipitation/ Western blot assays. Furthermore, anti-NXP-2 antibodies were not detected in 50 normal healthy control sera, either by ELISA or by immunoprecipitation/Western blotting (results in Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wi ley.com/doi/10.1002/art.40491/abstract). Thus, screening by ELISA, followed by confirmation with immunoprecipitation/Western blotting, revealed that 56 (7.9%) of the 709 enrolled patients were positive for anti-NXP-2 autoantibodies.
Clinical characteristics of the patients with anti-NXP-2 autoantibodies. The summary of clinical findings in IIM patients with and those without anti-NXP-2 autoantibodies is shown in Table 1 . Of the 56 IIM patients with anti-NXP-2 autoantibodies, 4 (7.1%) had PM, 39 (69.6%) had DM, 9 (16.1%) had juvenile DM, and 4 (7.1%) had NSM, while none of the anti-NXP-2-positive patients had IMNM or antisynthetase syndrome. The frequency of anti-NXP-2 autoantibodies varied considerably between adult patients and juvenile patients (6.9% versus 37.5%; P < 0.001).
Compared to patients without these autoantibodies, anti-NXP-2-positive patients were significantly younger at the time of disease diagnosis (P < 0.001) and exhibited a shorter duration of disease from the time of disease onset to the diagnosis of myositis (P = 0.03). The data obtained from patients in this study confirm those from recent studies with regard to the typical clinical characteristics of anti-NXP-2-positive IIM patients (13, 14) , including the presence of muscle weakness, myalgia, dysphagia, high peak CK levels, calcinosis, and subcutaneous edema in these patients. Moreover, anti-NXP-2-positive patients were less likely to have interstitial lung disease and arthralgia (both P < 0.001 versus anti-NXP-2-negative patients). Among the anti-NXP-2-positive patients, 3 had cancer (1 with gastric carcinoma, 1 with breast carcinoma, and 1 with nasopharyngeal carcinoma) during the 3 years before or after the onset of the IIM, but this was not statistically significantly different compared to anti-NXP-2-negative patients (P > 0.05).
Cross-sectional analysis of associations of disease activity with anti-NXP-2 levels. A cross-sectional analysis using the data from the 56 anti-NXP-2-positive patients was conducted at the time of initial evaluation to determine potential associations between anti-NXP-2 autoantibody levels and disease activity in different organ systems. Statistically significant positive correlations were found between anti-NXP-2 autoantibody levels and the physician's global assessment of disease activity VAS scores (q = 0.36, P = 0.006), muscle VAS scores (q = 0.38, P = 0.004), and serum CK levels (q = 0.29, P = 0.03).
In a subgroup analysis stratified by the presence or absence of calcinosis, the associations of disease activity with anti-NXP-2 autoantibody levels were maintained in the 38 anti-NXP-2-positive patients without calcinosis. However, such associations were not observed in the 18 patients with calcinosis ( Figure 1) .
Of the 18 anti-NXP-2-positive patients with calcinosis, 12 developed calcinosis at the time of initial evaluation, whereas 6 developed calcinosis during the follow-up period (range 8-29 months). Intriguingly, the levels of anti-NXP-2 autoantibodies were not correlated with the VAS scores for disease activity in each specific organ system or with the serum CK levels (all P > 0.05) in the 6 patients who developed calcinosis at * Except where indicated otherwise, values are the number (%) of patients with idiopathic inflammatory myopathy (IIM). Anti-NXP-2 = anti-nuclear matrix protein 2; DM = dermatomyositis; IQR = interquartile range; PM = polymyositis; IMNM = immune-mediated necrotizing myopathy; NSM = nonspecific myositis; ILD = interstitial lung disease; CK = creatine kinase. † Fisher's exact test was used to compare categorical variables, and Mann-Whitney U test was used to compare continuous variables. P < 0.05 was considered significant. ‡ Muscle weakness was defined as an aggregate score of <80 on the Manual Muscle Testing in 8 muscles (MMT-8) or as a grade of <10 on the Kendall MMT 10-point scale for one of the arm abduction or hip flexion strength tests, and analyses were stratified based on the different included muscle groups of manual muscle strength testing. § Consistent with that previously reported by Rogers et al (13) , subcutaneous edema was defined as any swelling of the extremity that met the following criteria: not attributable to synovitis, not associated with other causes of peripheral edema, new occurrence with disease onset, and a course that generally followed that of the IIM.
follow-up but who did not have calcinosis at the time of initial evaluation.
Longitudinal correlation of anti-NXP-2 levels with disease activity. A longitudinal investigation was performed to further explore the association of anti-NXP-2 autoantibody levels with disease activity. In total, 14 anti-NXP-2-positive patients (9 without calcinosis and 5 with calcinosis) who had at least 3 consecutive follow-up visits and for whom serum samples were available at each of the followup visits were included. For each patient, the interval between the 2 adjacent serum samples was 3-9 months, and 3-5 samples were obtained from each patient for longitudinal analysis.
When all subjects were analyzed together, a series of mixed linear regression analyses of repeated data showed significant positive correlations between the anti-NXP-2 antibody levels and the following clinical parameters: physician's global assessment of disease activity VAS scores, constitutional, cutaneous, gastrointestinal, and muscle VAS scores, and serum CK levels (all P < 0.05) ( Table 2) .
The patients were also further subdivided into those with and those without calcinosis. The same associations with the measures of disease activity mentioned above were maintained in the 9 anti-NXP-2-positive patients without calcinosis, whereas only physician's global assessment and constitutional VAS scores showed a Figure 1 . Correlation of anti-nuclear matrix protein 2 (anti-NXP-2) autoantibody levels with measures of myositis disease activity. Serum anti-NXP-2 autoantibody levels were determined with an in-house enzyme-linked immunosorbent assay using recombinant MORC3. Spearman's correlation analyses were used to test for correlations of anti-NXP-2 autoantibody levels with the physician's global assessment of disease activity (PhGA) visual analog scale (VAS) scores, muscle VAS scores, and creaine kinase (CK) levels in 38 patients without calcinosis (A) and 18 patients with calcinosis (B). The CK levels are expressed as the number of times the upper limit of normal (ULN). Asterisks indicate a significant correlation. * Assessments were made in 58 serial samples from 14 anti-nuclear matrix protein 2 (anti-NXP-2)-positive patients. P < 0.05 was considered significant. ELISA = enzyme-linked immunosorbent assay; PhGA = physician's global assessment of disease activity; VAS = visual analog scale; NA = not applicable; CK = creatine kinase. † Mixed linear regression analyses were performed to determine correlations between anti-NXP-2 autoantibody levels and disease activity.
moderate association with anti-NXP-2 autoantibody levels in patients with calcinosis ( 
abstract).
Dynamic changes in serum levels of anti-NXP-2 in patients without calcinosis. Given that the present cross-sectional and longitudinal analyses showed a close relationship between serum anti-NXP-2 autoantibody levels and the physician's global assessment of disease activity VAS scores in patients without calcinosis, it was further investigated whether disease remission was generally paralleled by the decrease or absence of anti-NXP-2 autoantibodies after therapy, and whether the antibody reappeared subsequent to a period of relapse. Therefore, we studied serial serum samples from the 9 patients without calcinosis and observed that, during a median follow-up of 24 months, 6 of the patients achieved clinical remission. In 5 of the 6 patients, the serum became negative for anti-NXP-2 autoantibodies during remission, Figure 2 . Longitudinal changes in anti-NXP-2 autoantibody levels and serum CK levels over time in 9 patients without calcinosis. Serum anti-NXP-2 autoantibody levels were determined with an in-house enzyme-linked immunosorbent assay using recombinant MORC3. The solid horizontal lines indicate the cutoff value, determined by measuring the reactivity of 50 healthy control sera with NXP-2, with the cutoff set at 5 standard deviations above the mean value in the healthy controls. See Figure 1 for definitions. Figure 3 . Longitudinal changes in anti-NXP-2 autoantibody levels and serum CK levels over time in 5 patients with calcinosis. Serum anti-NXP-2 autoantibody levels were determined with an in-house enzyme-linked immunosorbent assay using recombinant MORC3. The solid horizontal lines indicate the cutoff value, determined by measuring the reactivity of 50 healthy control sera with NXP-2, with the cutoff set at 5 standard deviations above the mean value in the healthy controls. See Figure 1 for definitions. while 1 of the patients still had anti-NXP-2 autoantibodies but the titer was dramatically reduced in the serum after therapy (from 135.71 units to 25.1 units). It was noteworthy that among these 5 patients, 2 experienced disease relapse, and during relapse, their serum again became positive for anti-NXP-2 antibodies, while the other 3 patients who remained negative for anti-NXP-2 had no relapse (Figure 2 Univariate predictors of the development of calcinosis. Among the 56 patients with anti-NXP-2 autoantibodies, 12 presented with calcinosis during the initial visit, whereas 44 patients did not exhibit calcinosis at the initial visit. Of these 44 patients with a follow-up visit and no calcinosis at baseline, 6 developed the condition during follow-up. Table 3 lists the characteristics of the patients without calcinosis at baseline according to whether calcinosis did or did not develop during follow-up. The results showed that patients who developed calcinosis during the follow-up had a predisposition toward high serum levels of anti-NXP-2 autoantibodies (median 70.9 units [IQR 33.5-98.0] in those with calcinosis during follow-up versus median 24.9 units [IQR 6.0-70.5] in those without calcinosis during follow-up); however, the difference did not reach statistical significance (P = 0.20). In addition, in patients who developed calcinosis, the interval from disease onset to the time of therapy was more prolonged than that in patients who did not develop calcinosis (P = 0.03).
Correlation of anti-NXP-2 levels with calcinosis severity. This study also examined whether any significant association existed between anti-NXP-2 autoantibody levels and the severity of calcinosis. Results of the Spearman's rank correlation tests revealed no association between anti-NXP-2 autoantibody levels and calcinosis severity (q = 0.05, P = 0.87).
A further review of the 5 patients with longitudinal data (ranging from 10 months to 42 months) showed that the calcinosis severity scores remained almost unchanged over time. In contrast, the anti-NXP-2 autoantibody levels fluctuated and even decreased below the cutoff level (3.2 units) over time.
DISCUSSION
The present study was the first to systematically explore the associations between anti-NXP-2 autoantibody levels and IIM disease activity as well as calcinosis severity. Interestingly, in this large longitudinal cohort study, heterogeneity with regard to the association of antibody levels with disease activity was found between patients with and those without calcinosis, although specific MSAs usually can be used to identify more homogeneous subsets of patients with autoimmune myopathy. Furthermore, no correlation between anti-NXP-2 autoantibody levels and calcinosis severity was observed in this study.
In the subgroup analysis of patients without calcinosis, a moderate to strong association between anti-NXP-2 autoantibody levels and physician's global assessment of disease activity VAS scores, muscle VAS scores, and serum CK levels was demonstrated in the cross-sectional assessment of 38 anti-NXP-2-positive patients. Furthermore, these associations were supported by the follow-up longitudinal analyses in 9 patients with IIMs without calcinosis, which not only revealed a more striking association but also extended the association of anti-NXP-2 autoantibody levels with other VAS scores of organ-specific disease activity, including the constitutional, cutaneous, and gastrointestinal disease activity scores. The conclusions made, based on the statistical associations observed, must be viewed with some caution because access to serial specimens was limited. However, a detectable change in the anti-NXP-2 autoantibody levels over time has the potential to serve clinically as an indicator for the assessment of active disease in extramuscular tissues, such as cutaneous and gastrointestinal organs. The relationship between anti-NXP-2 autoantibody levels and specific muscle and extramuscular manifestations suggests that anti-NXP-2 autoantibodies have a pathogenic link with their corresponding antigen in the affected tissue. Similar to the results of studies involving anti-Jo-1, anti-MDA-5, and anti-SRP autoantibodies (21, (32) (33) (34) , the levels of anti-NXP-2 autoantibodies may also normalize during disease remission. Moreover, the reappearance of anti-NXP-2 autoantibodies was associated with clinical relapse, whereas the serum levels remained negative in those who did not experience a relapse. These findings suggest that the examination of anti-NXP-2 autoantibody levels could potentially be used as a clinical tool for monitoring treatment response and disease relapse in patients with IIMs.
The subgroup analysis showed no statistically significant correlation between anti-NXP-2 autoantibody levels and serum CK levels or organ-specific disease activity at the time of initial evaluation in patients with calcinosis compared to patients without calcinosis. Meanwhile, a moderate association of anti-NXP-2 autoantibody levels with constitutional and physician's global disease activity scores, rather than with any other specific organ involvement, was seen longitudinally, further confirming the discrepancy in the association of anti-NXP-2 autoantibody levels with disease activity between patients with and those without calcinosis. Similar findings were reported by Werner et al in studies of anti-HMGCR autoantibodies; they found paralleled changes between anti-HMGCR autoantibody levels and CK levels in the subgroup of statin-exposed patients but not in unexposed patients (22) .
The differences between antibody-positive patients with and those without calcinosis might be reflective of the differing role and target of anti-NXP-2 autoantibodies in each group. Moreover, different triggers might be another reason for the differences between patients with and those without calcinosis. Increasing evidence has shown that MORC3 is a transcriptional regulator of proteins involved in the signal transduction pathway (interferon [IFN]-activated STAT, Akt, and MAPK) (35, 36) . Jadhav et al recently reported that a mutation in MORC3 resulted in the disequilibration of bone homeostasis and was associated with the up-regulation of inflammatory molecules, including IFNb/STAT-1 (37) . It is interesting to note that increased IFNb expression and its association with an up-regulated IFN signature were found in patients with DM, indicating that it might play important roles in the pathogenesis of myositis (38, 39) . This led to the speculation that a mutation in MORC3 in the different cells might be the original source involved in the development of IIMs and ectopic calcinosis.
Clinically, calcinosis is often unpredictable. This study explored whether evaluation of anti-NXP-2 autoantibody levels could identify those patients who might be at higher risk for developing calcinosis. The data suggested that anti-NXP-2 autoantibody levels alone did not determine whether a patient would develop clinically overt calcinosis, because no statistically significant difference in the serum anti-NXP-2 autoantibody levels was observed between patients who developed calcinosis at the followup and those who did not, despite the presence of higher median anti-NXP-2 autoantibody levels in patients with calcinosis (70.9 units versus 24.9 units in patients without calcinosis). Strikingly, in the baseline analysis, no association of anti-NXP-2 autoantibody levels with disease activity was observed in the patients who developed calcinosis at the follow-up. These findings might have important implications in managing patients with anti-NXP-2 autoantibodies. For instance, in patients displaying mild disease, especially those with no or mild muscle involvement, the serum levels of anti-NXP-2 autoantibodies were relatively high, suggesting a higher risk for calcinosis. Furthermore, this study demonstrated that the evolution of calcinosis was independent of muscle and extramuscular involvement, and anti-NXP-2 autoantibodies could not be used as a surrogate marker of calcinosis severity.
This study had several limitations. First, despite being the largest cohort study to date to systematically evaluate associations of anti-NXP-2 autoantibody levels with disease activity, the inclusion of patients from a single tertiary referral center might have introduced several possible biases. Second, the small sample size of patients with calcinosis for whom serial specimens were available might have precluded a determination of statistical significance, and therefore our findings need validation in larger prospective studies in the future.
Furthermore, currently no validated outcome measures are available to assess calcinosis severity in IIMs. Therefore, the cutaneous item in the MDI was used for assessing cutaneous damage, and the calcinosis lesion was presupposed to be the only cutaneous manifestation present. Although this had good face validity and was rated independently by 2 observers who reached consensus on each digit, the present study did not include formal interor intrarater reliability assessments for this scale.
Finally, Betteridge and McHugh reviewed previous studies on anti-NXP-2 autoantibodies and, based on their findings, they suggested that anti-NXP-2 autoantibodies covered a dual spectrum of clinical associations with calcinosis and cancer (3) . The cohort in the present study included only 3 anti-NXP-2-positive patients with cancer, and exclusion of the patients with cancer had no effect on the primary findings of these analyses (results not shown).
In summary, the present study demonstrated that serum anti-NXP-2 autoantibody levels were correlated with disease activity, and different associations between anti-NXP-2 levels and disease activity were found in patients with and those without calcinosis. No correlation was established between anti-NXP-2 autoantibody levels and disease activity in the early phase of the disease, which might be highly suggestive of an increased risk of calcinosis. The evaluation of the effect of anti-NXP-2 autoantibodies on the cultures of myogenic cells or keratinocytes and their passive transfer to animals would be useful in evaluating the role of anti-NXP-2 autoantibodies in the physiopathogenesis of IIMs.
